Epicutaneous immunotherapy on intact skin using a new delivery system in a murine model of allergy

Clinical and Experimental Allergy

Volumn 40, Issue 4, 2010, Pages 659-667

  Mondoulet, L ^a   Dioszeghy, V ^a   Ligouis, M ^a   Dhelft, V ^a   Dupont, C ^b   Benhamou, P H ^a  

^a DBV TECHNOLOGIES   (France)

^b HÔPITAL SAINT VINCENT DE PAUL   (France)

Author keywords

Allergy; Epicutaneous immunotherapy; House dust mite; Mouse model; Ovalbumin; Peanut; Pollen

Indexed keywords

FOOD ALLERGEN; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2A; METHACHOLINE; OVALBUMIN;

ALLERGY; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIGEN SPECIFICITY; ARTICLE; CONTROLLED STUDY; DERMATOPHAGOIDES; DRUG ADMINISTRATION ROUTE; DRUG DELIVERY SYSTEM; DRUG EFFICACY; EPICUTANEOUS IMMUNOTHERAPY; EXPERIMENTAL MODEL; FEMALE; FOOD; HOUSE DUST; IMMUNOTHERAPY; MOUSE; NONHUMAN; PEANUT; PLETHYSMOGRAPHY; POLLEN; PRIORITY JOURNAL; PROVOCATION; SENSITIZATION; SKIN; TREATMENT DURATION;

ANIMALS; ARACHIS HYPOGAEA; DESENSITIZATION, IMMUNOLOGIC; DISEASE MODELS, ANIMAL; FOOD HYPERSENSITIVITY; HUMANS; HYPERSENSITIVITY, IMMEDIATE; MICE; MICE, INBRED BALB C; OVALBUMIN; PEANUT HYPERSENSITIVITY; POLLEN; PYROGLYPHIDAE; RESPIRATORY HYPERSENSITIVITY; SKIN; TREATMENT OUTCOME;

EID: 77949360619     PISSN: 09547894     EISSN: 13652222     Source Type: Journal    
DOI: 10.1111/j.1365-2222.2009.03430.x     Document Type: Article

References (27)

1. Noon L. Prophylactic inoculation against hay fever. Lancet 1911; 2:1572-3.
2. Freeman J. Further observations on the treatment of hay fever by hypodermic inoculations of pollen vaccine. Lancet 1911; 2:814-7.
3. Bousquet J, Lockey R, Malling HJ. World Health Organization position paper. Allergen immunotherapy: therapeutis = cal vaccines for allergic diseases. Allergy 1998; 53:20-7.
4. Larche M. Specific Immunotherapy. Brit Med Bull 2000; 56:1019-36.
5. Gehlhar K, Schlaak M, Becker W, Bufe A. Monitoring allergen immunotherapy of pollen-allergic patients: the ratio of allergen-specific IgG4 to IgG1 correlates with clinical outcome. Clin Exp Allergy 1999; 29:497-506.
6. Pichler CE, Helbling A, Pichler WJ. Three years of specific immunotherapy with house-dust-mite extracts in patients with rhinitis and asthma: significant improvement of allergen-specific parameters and of non-specific bronchial hyperreactivity. Allergy 2001; 56:301-6.
7. M̈oller C, dreborg S, Ferdousi HA et al. Pollen immunotherapy reduces the development of asthma in children with seasonal rhinoconjunctivitis (the PATStudy). J Allergy Clin Immunol 2002; 109:251-6.
8. Till SJ, Durham SR. Immunologic responses to subcutaneous allergen immunotherapy. Clin Allergy Immunol 2008; 21:59-70.
9. Bousquet J. Sublingual immunotherapy: validated. Allergy 2006; 61:5-6.
10. Wiedermann U, Jahn-Schmid B, Fritsch R et al. Effects of adjuvants on the immune response to allergens in a murine model of allergen inhalation: cholera toxin induces a Th1-like immune response to Bet v1, the major birch pollen allergen. Clin Exp Allergy 1998; 111:144-51.
11. Lagranderie M, Abolhassani M, Vanoirbeek J et al. Mycobacterium bovis BCG killed by extended freeze-drying reduces airway hyperresponsiveness in 2 animal models. J Allergy Clin Immunol 2008; 121:471-8.
12. Kalach N, Soulaines P, de Boissieu D, Dupont C. A pilot study of the usefulness and safety of a ready-to-use atopy patch test (Diallertest) versus a comparator (Finn Chamber) during cow's milk allergy in children. J Allergy Clin Immunol 2005; 116:1321-6.
13. Pautrizel R, Cabanieu G, Bricaud H, Broustet P. Allergenic group specificity & therapeutic consequences in asthma; specific desensitization method by epicutaneous route. Sem Hop 1957; 33:1394-403.
14. Hamelmann E, Schwarze J, Takeda K et al. Noninvasive measurement of airway responsiveness in allergic mice using barometric plethysmography. Am J Respir Crit Care Med 1997; 156:766-75.
15. Brimnes J, Kildsgaard J, Jacobi H, Lund K. Sublingual immunotherapy reduces allergic symptoms in a mouse model of rhinitis. Clin Exp Allergy 2006; 37:488-97.
16. Van Oosterhout AJML, Van Esch B, Hofman G et al. Allergen immunotherapy inhibits airway eosinophilia and hyperresponsiveness associated with decreased IL-4 production by lymphocytes in a murine model of allergic asthma. Cell Mol Biol 1998; 19:622-8.
17. Conejero L, Higaki Y, Baeza ML, Fernandez M, Varela-Nieto I, Zubeldia JM. Pollen-induced airway inflammation, hyperresponsiveness and apoptosis in a murine model of allergy. Clin Exp Allergy 2009; 37:331-8.
18. Conrad ML, Yildirim AO, Sonar SS et al. Comparison of adjuvant and adjuvant-free murine experimental asthma models. Clin Exp Allergy 2009; 39:1246-54.
19. Wang J, Palmer K, Lotvall J et al. Circulating, but not local lung, IL-5 is required for the development of antigen-induced airways eosinophilia. J Clin Invest 1998; 102:1132-41.
20. Spergel J, Mizoguchi E, Brewer JP, Martin TR, Bahn AK, Geha RS. Epicutaneous Sensitization with Protein Antigen Induces Localized Allergic Dermatitis and Hyperresponsiveness to Methacholine after Single Exposure to Aerosolized Antigen in Mice. J Clin Invest 1998; 101:1614-22.
21. Mondoulet L, Dioszeghy V, Ligouis M, Berchet A, Dupont C, Benhamou PH. Dose effect of epicutaneous immunotherapy (EPIT) for peanut allergy in murine model. 2009, EAACI, June 2009, Warsaw.
22. Eyerich K, Huss-Marp J, Darsow U et al. Pollen grains induce a rapid and biphasic eczematous immune response in atopic eczema patients. Int Arch Allergy Immunol 2008; 145:213-23.
23. Dioszeghy V, Mondoulet L, Dhelft V, Dupont C, Benhamou PH. In epicutaneous immunotherapy, application of allergen on intact skin results in rapid uptake by the dendritic cells in sensitized mice. EAACI Congress, 2009.
24. Dioszeghy V, Mondoulet L, Dhelft V, Dupont C, Benhamou PH. Epicutaneous immunotherapy, application of allergen on intact skin result on rapid uptake by the dendritic cells in sensitized mice. EEACI Congress, 2009.
25. Strid J, Hourihane J, Kimber I, Callard R, Strobel S. Epicutaneous exposure to peanut protein prevents oral tolerance and enhances allergic sensitization. Clin Exp Allergy 2005; 35:757-66.
26. Strid J, Thomson M, Hourihane J, Kimber I, Strobel S. A novel model of sensitization and oral tolerance to peanut protein. Immunology 2004; 113:293-303.
27. Strid J, Callard R, Strobel S. Epicutaneous immunization converts subsequent and established antigen-specific T helper type 1 (Th1) to Th2-type responses. Immunology 2006; 119:27-35.